TARGET achieves 98.5% three-year control within focal prostate boost volumes

In TARGET, focal VMAT or HDR brachytherapy boosts achieved 98.5% three-year control within treated prostate lesions, while four recurrences arose outside the boost.

KEY POINTS

  • TARGET (NCT01802242) was a prospective, single-center, nonrandomized phase II trial conducted at Princess Margaret Cancer Centre, Toronto, enrolling 80 patients with localized prostate cancer between November 2012 and August 2016. Forty patients received an integrated VMAT boost and 40 an HDR brachytherapy boost. Median age was 70 years, 75% had intermediate-risk disease, and only three patients received six months of androgen deprivation therapy (ADT). Median follow-up was 4.8 years (IQR 4.0–8.0).
  • All patients received whole-prostate VMAT to 76 Gy in 38 fractions, with focal escalation directed at an MRI-defined intraprostatic lesion. The integrated boost cohort received 95 Gy in 38 fractions (IB-VMAT), while the brachytherapy cohort received a single 10-Gy MRI-guided HDR boost approximately one week before VMAT (HDR-VMAT). The boost PTV expansion was 5 mm anterior-posterior/superior-inferior and 3 mm left-right for IB-VMAT, compared with 2 mm and 1 mm, respectively, for HDR-VMAT, with OAR exclusion for the latter.
  • Three-year local control within the boost volume, the primary endpoint, reached 98.5% (65/66 evaluable patients). Among 66 patients completing MRI (n=46) or MRI-guided biopsy (n=20) at three years, only one patient developed recurrence within the original boost volume, confirmed by biopsy in the IB-VMAT cohort. The remaining 14 patients did not complete the primary endpoint assessment because of death unrelated to prostate cancer, withdrawal, loss to follow-up, or refusal of imaging.
  • Four additional intraprostatic recurrences occurred outside the original boost volume, including three after HDR-VMAT and one after IB-VMAT. Two were identified at the three-year assessment and two during subsequent follow-up. Three patients developed regional or distant metastatic progression, including two with simultaneous local recurrence outside the boosted region. These findings suggest that microscopic disease beyond MRI-defined lesions and occult multifocal disease may remain important limitations of focal escalation.
  • Biochemical outcomes were favorable with both techniques. Eight patients developed biochemical failure, four in each cohort. Overall five-year biochemical failure-free survival (bFFS) was 86.9% (95% CI 79.1–95.5%), with estimates of 82.5% (95% CI 70.5–96.6%) after HDR-VMAT and 90.9% (95% CI 81.4–100%) after IB-VMAT. The between-cohort comparison was not statistically significant (log-rank p=0.881), and the study was not designed to establish comparative efficacy.
  • Late grade 2 toxicity was broadly comparable between the two strategies. Grade 2 genitourinary toxicity occurred in 22.5% after HDR-VMAT versus 25.0% after IB-VMAT, while grade 2 gastrointestinal toxicity occurred in 7.5% versus 5.0%, respectively. One IB-VMAT patient developed a late grade 3 rectal fistula while receiving concurrent antiretroviral therapy. Another experienced grade 3 hematuria related to a newly diagnosed bladder cancer, considered unrelated to prostate radiotherapy. No additional grade 3 events emerged during extended follow-up.
  • Patient-reported urinary and bowel function generally recovered within three to six months, whereas sexual function remained below baseline throughout follow-up. At three years, clinically meaningful deterioration in urinary bother was less frequent after HDR-VMAT than IB-VMAT (9.4% vs 33.3%; p=0.02), while other EPIC outcomes did not differ significantly. This exploratory finding is limited by nonrandom treatment allocation, baseline differences between cohorts, and missing follow-up responses. The conventional 38-fraction schedules and minimal ADT use also limit direct applicability to contemporary hypofractionated treatment.

CLINICAL TAKEAWAY

MRI-guided focal dose escalation using either integrated VMAT or HDR brachytherapy boost achieved excellent three-year control of visible intraprostatic lesions with generally acceptable late toxicity. However, recurrence outside the boosted region highlights the importance of defining subclinical disease and potentially integrating additional imaging such as PSMA PET. The nonrandomized study does not establish superiority of either boost technique, and its treatment schedules differ from current hypofractionated practice.

SOURCE

Radiotherapy and Oncology

Browse more research Suggest a correction